Compare KREF & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | MNPR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.3M | 421.0M |
| IPO Year | 2017 | 2019 |
| Metric | KREF | MNPR |
|---|---|---|
| Price | $8.25 | $69.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $10.63 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 980.6K | 325.4K |
| Earning Date | 02-02-2026 | 11-13-2025 |
| Dividend Yield | ★ 12.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,012,000.00 | N/A |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.55 | $24.00 |
| 52 Week High | $11.53 | $105.00 |
| Indicator | KREF | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 50.19 |
| Support Level | $7.77 | $57.86 |
| Resistance Level | $8.36 | $66.65 |
| Average True Range (ATR) | 0.24 | 5.60 |
| MACD | -0.00 | 0.99 |
| Stochastic Oscillator | 64.65 | 82.22 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.